Researchers at Baylor College of Medicine, the Broad Institute of MIT and Harvard, along with clinicians at Washington University in St. Louis have identified biological markers in triple negative breast cancer that are associated with resistance to chemotherapy treatment.
Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer improved long-term survival overall compared with chemotherapy alone, according to a clinical trial published June 2 in The New England Journal of Medicine and presented at the annual meeting of the American Society of Clinical Oncology.
